Bojan Mitrovic

Dr. Bojan Mitrovic

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2022 in Archives of Medical Science
Verified
Journal Article
Open access
BMBojan Mitrovic
Bojan Mitrovic
MOMilan Obradovic
Milan Obradovic
ZGZoran Gluvic
Zoran Gluvic
MRMaja Radunovic
Maja Radunovic
MANFREDI RIZZOMANFREDI RIZZO
MANFREDI RIZZO
EIEsma Isenovic
Esma Isenovic
Non-alcoholic fatty liver disease (NAFLD), metabolic syndrome (MetS), and type 2 diabetes (T2DM) are metabolic disorders that belong to highly prevalent disease cluster with a significant impact on public health worldwide. MetS is a complex condition characterized by metabolism perturbations that include glucose intolerance, insulin resistance, dyslipidemia, associated pro-inflammatory state and arterial hypertension. As the components of MetS commonly co-occur, the management of these disorders could not be considered separate issues. Thus NAFLD, recognized as a hepatic manifestation of MetS, is frequently associated with T2DM. This review analyzes the underlying connections between these diseases and the risks associated with their co-occurrence. The effective management of NAFLD associated with MetS and T2DM involves an early diagnosis and optimal treatment of each condition leading to improvement in glycemic and lipids regulation, liver steatosis, and arterial hypertension. The net effect of such treatment is the prevention of atherosclerotic cardiovascular diseases and liver fibrosis.

1 January 2022 in Endocrine, Metabolic & Immune Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
BMBojan Mitrovic
Bojan Mitrovic
ZGZoran Gluvic
Zoran Gluvic
DMDjuro Macut
Djuro Macut
MOMilan Obradovic
Milan Obradovic
ESEmina Sudar-Milovanovic
Emina Sudar-Milovanovic
EIEsma Isenovic
Esma Isenovic
Background and Objectives : Non-alcoholic fatty liver disease (NAFLD) is associated with inflammation and subsequent increase in cardiovascular risk. Because of its widespread presence and distribution, invasive diagnostic procedures (i.e., liver biopsy) are reserved for a limited number of subjects. With liver ultrasound, Fatty liver index (FLI) and fibrosis-4 (FIB-4) scores non-invasively assess liver steatosis and fibrosis. We aimed to evaluate the changes in inflammatory markers and FLI/FIB-4 scores in non-obese metformin-treated type 2 diabetes patients (T2DM) with NAFLD. Methods: All subjects underwent abdominal ultrasound aiming for NAFLD stratification (grade 1 to 3 according to its severity). Metabolic parameters (morning glycaemia, HbA1C, lipids, liver function tests) and serum inflammatory markers (C-reactive protein, ferritin, and nitric oxide), and FLI/FIB-4 are calculated. Results: FLI score and ultrasound NAFLD grades correlated (p<0.05). We observed a significant correlation between the levels of ferritin and C-reactive protein (CRP) (p<0.05), and the FLI (p<0.05). Body weight (BW) (p<0.05), waist circumference (WC) (p<0.05), the levels of HbA1c (p<0.05), transferrin (p<0.05), insulin (p<0.05), and FLI score (p<0.05) significantly differed between groups defined by the severity of NAFLD. Conclusion: This pilot study suggests that the serum inflammatory markers at the average normal values point to the sufficiency of metformin-single therapy in inflammation control in non-obese T2DM patients with NAFLD.

1 February 2024 in Current Problems in Cardiology
Verified
Journal Article
Closed access
DBDzudovic Boris
Dzudovic Boris
STSimpson Tamara
Simpson Tamara
DIDjuric Ivica
Djuric Ivica
SBSubotic Bojana
Subotic Bojana
MJMatijasevic Jovan
Matijasevic Jovan
OSObradovic Slobodan
Obradovic Slobodan

25 April 2025 in Cancer Medicine
Verified
Journal Article
Open access
SSSonja Salinger
Sonja Salinger
AKAleksandra Kozic
Aleksandra Kozic
BDBoris Dzudovic
Boris Dzudovic
BSBojana Subotic
Bojana Subotic
JMJovan Matijasevic
Jovan Matijasevic
SOSlobodan Obradovic
Slobodan Obradovic
Background: Newly or already diagnosed cancer might significantly influence the clinical presentation, outcome, and therapy of acute pulmonary embolism (PE). Methods: Out of 1745 patients with acute PE, 66 patients were diagnosed with cancer during an initial hospitalization due to acute PE (where PE was the first clinical manifestation of cancer), 165 patients had known cancer treated in the last 6 months, and 1514 patients had acute PE without known or suspected cancer. The primary end‐point of the present study was all‐cause hospital death. The secondary end‐points were the proportion of patients treated with thrombolysis and who had severe disease, and the ocurrence of major or clinically relevant nonmajor bleeding. Results: Patients with PE as the first presentation of cancer had the highest hospital mortality rate compared to the other two groups (HR for the mortality rate in patients without cancer as a reference, adjusted to four‐stratum mortality risk, and Charlson's comorbidity index was 3.440; 95% confidence interval (CI), 1.795–6.591; p < 0.001). Patients with known cancer before PE had a significantly lower chance of being treated with thrombolysis than patients without cancer (OR, 0.523; 95% CI, 0.339–0.807; p = 0.003); additionally, this difference was attenuated but remained when the OR was adjusted to age (OR, 0.542; 95% CI, 0.351–0.838; p = 0.006). Patients with known cancer had a higher frequency of high‐risk PE compared with patients without cancer (18.2% vs. 12.8%; p < 0.001). Patients with PE as the first manifestation of cancer had a higher frequency of intermediate‐high‐risk PE than those without (36.4% vs. 30.9%; p < 0.001). There was no significant difference in bleeding during hospitalization between groups. Conclusion: Patients with cancer had a more severe presentation of acute PE than patients without. Furthermore, patients with PE as the first manifestation of cancer had the highest hospital mortality rate, and patients with known cancer were least likely to be treated with thrombolysis.

1 January 2022 in Acta Endocrinologica (Bucharest)
Verified
Journal Article
Closed access
BMBojan Mitrovic
Bojan Mitrovic
ZGZ. Gluvic
Z. Gluvic
AKA. Klisic
A. Klisic
MOMilan Obradovic
Milan Obradovic
DMD. Macut
D. Macut
EIE.R. Isenovic
E.R. Isenovic
Context. Prognostic considerations include assessing the risk of liver fibrosis in people with nonalcoholic fatty liver disease (NAFLD). Objectives. This study evaluates the use of hematologic and metabolic parameters regarding liver steatosis and fibrosis scores (FLI and Fib-4) in non-obese type 2 diabetes mellitus (t2DM) patients with NAFLD. Methods. Subjects underwent abdominal ultrasound examinations, and FLI and Fib-4 scores were calculated to evaluate liver steatosis and the risk of liver fibrosis non-invasively: 61 non-obese NAFLD subjects with t2DM were included in the cohort study and were divided into 2 groups depending on the t2DM treatment regimen. Results. Fib-4 and WBC count demonstrated a significant inverse correlation (OR = 0.509, p = 0.007). WBC count had an R2 of 0.237, indicating that this marker could account for up to 23.7% of a variation in Fib-4. Fib-4 and FFA had positive correlation which did not achieve statistically significant prediction (OR=7.122, p=0.062). Additionally, a significant prediction of HbA1c (OR=1.536, p=0.016) and haemoglobin (OR=1.071, p=0.020) for FLI was revealed. Conclusion. HbA1c and other haematological and metabolic parameters, such as haemoglobin and WBC, may be another non-invasive tool for determining whether non-obese NAFLD patients with t2DM are at risk of developing liver steatosis and fibrosis.

4 June 2025 in Thrombosis Research
Verified
Journal Article
Closed access
BDBoris Dzudovic
Boris Dzudovic
STSimpson Tamara
Simpson Tamara
MJMatijasevic Jovan
Matijasevic Jovan
PSPekovic Sandra
Pekovic Sandra
SSSalinger Sonja
Salinger Sonja
OSObradovic Slobodan
Obradovic Slobodan